SK10742003A3 - Vodná kompozícia amfotericínu B - Google Patents

Vodná kompozícia amfotericínu B Download PDF

Info

Publication number
SK10742003A3
SK10742003A3 SK1074-2003A SK10742003A SK10742003A3 SK 10742003 A3 SK10742003 A3 SK 10742003A3 SK 10742003 A SK10742003 A SK 10742003A SK 10742003 A3 SK10742003 A3 SK 10742003A3
Authority
SK
Slovakia
Prior art keywords
amphotericin
sodium chloride
phospholipids
composition
micronized
Prior art date
Application number
SK1074-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Srikanth Pai
Sangeeta Rivankar
Original Assignee
Bharat Serums & Vaccines Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums & Vaccines Ltd. filed Critical Bharat Serums & Vaccines Ltd.
Publication of SK10742003A3 publication Critical patent/SK10742003A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SK1074-2003A 2001-03-01 2001-03-16 Vodná kompozícia amfotericínu B SK10742003A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN217MU2001 IN188924B (he) 2001-03-01 2001-03-01
PCT/IN2001/000040 WO2002069983A1 (en) 2001-03-01 2001-03-16 Amphotericin b aqueous composition

Publications (1)

Publication Number Publication Date
SK10742003A3 true SK10742003A3 (sk) 2004-01-08

Family

ID=11097223

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1074-2003A SK10742003A3 (sk) 2001-03-01 2001-03-16 Vodná kompozícia amfotericínu B

Country Status (23)

Country Link
US (1) US20040137049A1 (he)
EP (1) EP1368041B1 (he)
JP (1) JP2004523566A (he)
KR (1) KR100810067B1 (he)
CN (1) CN1255114C (he)
AT (1) ATE274913T1 (he)
AU (1) AU2001250643B2 (he)
BG (1) BG108188A (he)
BR (1) BR0116922A (he)
CA (1) CA2438847A1 (he)
CZ (1) CZ20032264A3 (he)
DE (1) DE60105322T2 (he)
DK (1) DK1368041T3 (he)
EA (1) EA006241B1 (he)
ES (1) ES2227172T3 (he)
IN (1) IN188924B (he)
MX (1) MXPA03007777A (he)
NZ (1) NZ528281A (he)
PT (1) PT1368041E (he)
SK (1) SK10742003A3 (he)
WO (1) WO2002069983A1 (he)
YU (1) YU75403A (he)
ZA (1) ZA200307307B (he)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006069929A (ja) * 2004-08-31 2006-03-16 Konica Minolta Medical & Graphic Inc 真菌症治療製剤およびその製造方法
WO2006030450A2 (en) * 2004-09-13 2006-03-23 Bharat Serums & Vaccines Ltd. Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN100418536C (zh) * 2005-04-06 2008-09-17 河南省眼科研究所 一种用于眼科的抗真菌药物组合物
CN101453982B (zh) 2006-05-30 2011-05-04 精达制药公司 两件式内部通道渗透递送系统流动调节器
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CN104323981B (zh) 2009-09-28 2019-03-12 精达制药公司 基本稳态药物递送的快速建立和/或终止
KR101629521B1 (ko) * 2010-03-16 2016-06-13 우석대학교 산학협력단 난용성 약물 가용화 및 생체막 투과증진을 위한 알코올성 수상을 내상으로 하는 리포좀, 리포좀 조성물 및 리포좀의 제조방법
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102525921B (zh) * 2012-02-06 2013-08-07 西安力邦制药有限公司 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法
WO2013142184A1 (en) * 2012-03-19 2013-09-26 Yale University Antimicrobial compositions and methods
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3222324B1 (en) * 2016-03-23 2020-05-13 Wayne State University Valproate as a topical anti-fungal treatment
MX2018014016A (es) 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
CN108344811A (zh) * 2017-01-24 2018-07-31 北京泰德制药股份有限公司 一种注射用脂质体中有机溶剂残留的检测方法
CN108309955B (zh) * 2018-04-27 2020-06-02 武昌理工学院 一种聚明胶肽结合型紫杉醇纳米颗粒的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
JP3956402B2 (ja) * 1996-03-04 2007-08-08 日本油脂株式会社 アンホテリシンb運搬体
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use

Also Published As

Publication number Publication date
JP2004523566A (ja) 2004-08-05
DE60105322T2 (de) 2005-09-15
ATE274913T1 (de) 2004-09-15
ZA200307307B (en) 2004-04-20
CZ20032264A3 (cs) 2003-12-17
IN188924B (he) 2002-11-23
BG108188A (bg) 2004-09-30
CA2438847A1 (en) 2002-09-12
EP1368041B1 (en) 2004-09-01
KR100810067B1 (ko) 2008-03-05
AU2001250643B2 (en) 2007-03-22
CN1505519A (zh) 2004-06-16
DE60105322D1 (de) 2004-10-07
US20040137049A1 (en) 2004-07-15
WO2002069983A1 (en) 2002-09-12
DK1368041T3 (da) 2005-01-17
CN1255114C (zh) 2006-05-10
ES2227172T3 (es) 2005-04-01
EA006241B1 (ru) 2005-10-27
KR20040018337A (ko) 2004-03-03
EA200300948A1 (ru) 2004-04-29
BR0116922A (pt) 2004-04-27
NZ528281A (en) 2006-11-30
YU75403A (sh) 2006-05-25
MXPA03007777A (es) 2003-12-08
PT1368041E (pt) 2005-01-31
EP1368041A1 (en) 2003-12-10

Similar Documents

Publication Publication Date Title
SK10742003A3 (sk) Vodná kompozícia amfotericínu B
AU2002312777B2 (en) Method and composition for solubilising a biologically active compound with low water solubility
CN102018714B (zh) 制剂
AU2001250643A1 (en) Amphotericin B aqueous composition
EP1682116B1 (en) Method for preparing submicron particles of paclitaxel or docetaxel
AU2002312777A1 (en) Method and composition for solubilising a biologically active compound with low water solubility
KR20060135729A (ko) 중추신경계 전달 증가를 위한 항레트로바이러스제의나노현탁액
CN1044093C (zh) 低毒性药物类脂制剂
RU2391966C1 (ru) Наносистема на основе растительных фосфолипидов для включения биологически активных соединений и способ ее получения (варианты)
JPH11507369A (ja) プレリポソーム凍結乾燥体から得られるサブミクロンリポソーム懸濁液
JP2798302B2 (ja) リポソームおよび脂質複合体組成物の調製
MX2007007442A (es) Modificadores de superficie de (polialcoxi)sulfonato.
NO880403L (no) Parenterale suspensjoner.
AU634644B2 (en) Parenterally administrable lipsome formulation comprising synthetic lipids
CN110974937B (zh) 一种多粘菌素e脂质体及其制备方法和应用
US5720973A (en) Preparation of colloidal aqueous solutions of active substances of low solubility and a lipid therefor
UA64591A (en) Method for producing lyposomal composition of anticancer antibiotic
MXPA06008533A (en) Nanosuspensions of anti-retroviral agents for increased central nervous system delivery